Search
Talampanel
go.drugbank.com/drugs/DB04982InvestigationalTalampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
Tozorakimab
go.drugbank.com/drugs/DB16473InvestigationalCOPD patients with a history of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions.
BACTEK-R
go.drugbank.com/drugs/DB16526InvestigationalMV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. … Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
Cyclic GMP
go.drugbank.com/drugs/DB02315ExperimentalIts levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) … Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions.
Pipecuronium
go.drugbank.com/drugs/DB01338ApprovedInvestigationalWithdrawnPipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning … R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential.
SW033291
go.drugbank.com/drugs/DB32765Experimental[A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474] … SW033291 is a small molecule 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor.
Tenamfetamine
go.drugbank.com/drugs/DB01509IllicitInvestigationalAn amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. … It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]